AzTrials
AzTrials

Heart FailurePhase 2/3EchoCRTNCT00683696

Echocardiography Guided Cardiac Resynchronization Therapy (EchoCRT)

A Phase 2/3 study testing Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D) in people with Heart Failure and Ventricular Dyssynchrony, run by Biotronik, Inc. at 122 sites in 17 countries.

Terminated

Stopped early. The study ended before it was planned to and will not resume.

Official record
Search all trials

Trial summary

The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (< 130 ms) and echocardiographic evidence of ventricular… Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Heart Failure, Ventricular Dyssynchrony
What is being tested?
Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
1,680 participants
Where
122 sitesin 17 countries
Study dates
Aug 2008to Mar 2013
Phase
Phase 2/3
Are there results?
Yes, posted in the registrySummary in the doctors' view

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Who may be able to join

  • Men and women 18 years of age or older.
  • Understand the nature of the procedure.
  • Give written informed consent.
  • Willing and able to complete all testing required by the clinical protocol.
  • Indication for an implantable cardioverter defibrillator (ICD).
  • NYHA class III-IV within the last three months prior to enrollment and at baseline (at baseline only: also Stage C according to ACC/AHA guidelines).
Show all 13Show fewer
  • Stable optimal pharmacologic therapy for HF.
  • An ejection fraction ≤ 35% within one year prior to enrollment and confirmed on the baseline echocardiogram.
  • Increased left ventricular dimension, defined as LVEDD ≥ 55 mm.
  • Resting QRS duration < 130 ms evidenced by a historical 12-lead ECG prior to enrollment and at baseline.
  • Ventricular dyssynchrony assessed by echocardiography locally and confirmed by the echo core lab. One of the two following criteria has to be present to include the subject in the study:
  • Intra-left ventricular dyssynchrony measured by color Tissue Doppler Imaging (TDI) with an opposing wall delay of ≥ 80 ms in the 4-chamber or apical long-axis view.
  • Speckle-tracking radial strain septal-posterior wall delay ≥ 130 ms.

Who cannot join

  • Implanted pacemaker or defibrillator with >10% ventricular pacing, as demonstrated by device statistics averaged over at least the last three months prior to enrollment.
  • Women who are pregnant, lactating, or planning to become pregnant during the course of the trial.
  • Bradycardia pacing indication.
  • Surgically correctable primary valvular heart disease, i.e. aortic stenosis, torn cordae, or flail segment.
  • Coronary artery bypass graft surgery or percutaneous coronary intervention (balloon and/or stent angioplasty) within the past 3 months prior to enrollment.
  • Enzyme-positive myocardial infarction within the past 3 months prior to enrollment.
Show all 23Show fewer
  • Angiographic evidence of coronary disease, candidates for coronary revascularization likely to undergo coronary artery bypass graft surgery or percutaneous coronary intervention in the next 3 months.
  • Irreversible brain damage from preexisting cerebral disease.
  • Reversible non-ischemic cardiomyopathy such as acute viral myocarditis.
  • Permanent second or third degree heart block.
  • Chagas disease.
  • Persistent or paroxysmal atrial fibrillation within one month prior to enrollment.
  • Expected to receive heart transplantation within six months.
  • Current inotropic therapy.
  • Acutely decompensated heart failure.
  • Contrast dye allergy and unable or unwilling to undergo pretreatment with steroids and/or diphenhydramine.
  • Life expectancy of less than six months.
  • Presence of any disease, other than the subject's cardiac disease associated with a reduced likelihood of survival for the duration of the trial, (e.g. cancer).
  • Significant renal insufficiency defined as a serum creatinine > 2.5 mg/dL (> 221 µmol/L) within the last four weeks prior to enrollment..
  • Liver failure, defined as three times the upper limit of normal for aminotransferases.
  • Participation in any other clinical trial.
  • Unable to return for follow-up visits due to distance from the clinic.
  • Do not anticipate being a resident of the area for the scheduled duration of the trial.

Trial locations and contacts

122 sites in 17 countries.

122 sites in 17 countries

United States62 sites

  • Lehigh Valley Heart Specialists

    Allentown, Pennsylvania, 18103

  • Cardiology Center of Amarillo

    Amarillo, Texas, 79106

  • Piedmont Hospital

    Atlanta, Georgia, 30309

  • Emory University

    Atlanta, Georgia, 30322

  • Saint Joseph's Hospital

    Atlanta, Georgia

  • Texas Cardiac Arrhythmia

    Austin, Texas, 78705

  • Bay Regional Medical Center

    Bay City, Michigan, 48708

  • Massachusetts General Hospital

    Boston, Massachusetts, 02114-2696

  • Boston Medical Center

    Boston, Massachusetts, 02118

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts, 02215

  • Boston Medical Center

    Boston, Massachusetts

  • Deborah Heart and Lung Center

    Browns Mills, New Jersey, 08015

  • Sanger Heart & Vascular Institute

    Charlotte, North Carolina, 28203

  • University of Virginia

    Charlottesville, Virginia, 22908

  • Northwestern University

    Chicago, Illinois, 60611

  • Lindner Clinical Trial Center

    Cincinnati, Ohio, 45219

  • University of Cincinnati

    Cincinnati, Ohio, 45219

  • Cleveland Clinic

    Cleveland, Ohio, 44145

  • South Carolina Heart Center

    Columbia, South Carolina, 29204

  • The Ohio State University Richard M. Ross Heart Hospital

    Columbus, Ohio, 43210

  • John Muir Medical Center

    Concord, California, 94520

  • Cardiology Associates of Corpus Christi

    Corpus Christi, Texas, 78404

  • Duke University

    Durham, North Carolina

  • INOVA Fairfax Hospital

    Falls Church, Virginia, 22042

  • Hartford Hospital

    Hartford, Connecticut, 06102

  • St. Francis Medical Group

    Indianapolis, Indiana, 46237

  • Community Heart and Vascular

    Indianapolis, Indiana, 46250

  • Kansas City Heart Foundation

    Kansas City, Missouri, 64132

  • Research Medical Center

    Kansas City, Missouri, 64132

  • Research Medical Center

    Kansas City, Missouri

  • Osceola Regional Medical Center

    Kissimmee, Florida, 34741

  • Thoracic & Cardiovascular Healthcare Foundation

    Lansing, Michigan, 48910

  • Central Baptist Hospital

    Lexington, Kentucky, 40503

  • Cedars-Sinai Medical Center

    Los Angeles, California, 90048

  • Bon Secours Heart & Vascular Institute

    Mechanicsville, Virginia, 23116

  • The Stern Cardiovascular Center

    Memphis, Tennessee, 38138

  • University of Miami

    Miami, Florida, 33136

  • Aurora Cardiovascular Services

    Milwaukee, Wisconsin, 53215

  • St. Lukes-Roosevelt Hospital Center

    New York, New York, 10025

  • Drexel Cardiology

    Philadelphia, Pennsylvania, 19107

  • Jefferson Heart Institute, Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107

  • University of Pittsburgh Medical Center

    Pittsburgh, Pennsylvania, 15213

  • Oregon Health Sciences University

    Portland, Oregon, 97239

  • Desert Cardiology

    Rancho Mirage, California, 92270

  • Virginia Cardiovascular Specialists

    Richmond, Virginia, 23225

  • Bon Secours Heart & Vascular Institute

    Richmond, Virginia

  • Virginia Cardiovascular Specialists

    Richmond, Virginia

  • University of Rochester

    Rochester, New York, 14642

  • United Heart and Vascular Center

    Saint Paul, Minnesota, 55102

  • University of California San Francisco

    San Francisco, California, 94143

  • Kootenai Heart Clinics

    Spokane, Washington, 99204

  • Washington University

    St Louis, Missouri, 63102

  • Stony Brook University Medical Center

    Stony Brook, New York, 11794

  • Tampa General Hospital

    Tampa, Florida, 33606

  • Tampa General Medical Center

    Tampa, Florida

  • Montefiore Medical Center

    The Bronx, New York, 10467

  • Promedica Northwest Ohio Cardiology Consultants

    Toledo, Ohio, 43615

  • North Mississippi Medical Center

    Tupelo, Mississippi

  • Cardiology Associates Medical Group

    Ventura, California, 93003

  • Cardiovascular Associates Ltd

    Virginia Beach, Virginia, 23454

  • University of Massachusetts

    Worcester, Massachusetts, 01655

  • Michigan Heart, P.C./ St. Joseph Mercy Hospital

    Ypsilanti, Michigan, 48197

Other trials in United States

Germany14 sites

  • Herz- und Diabeteszentrum NRW

    Bad Oeynhausen

  • Charite Campus Virchow Klinikum

    Berlin

  • Judisches Krankenhaus Berlin

    Berlin

  • Evangelisch-Freikirchliches Krankenhaus und Herzzentrum Brandenburg in Bernau

    Bernau

  • Alfried Krupp Krankenhaus

    Essen

  • Elisabeth-Krankenhaus Essen

    Essen

  • Westdeutsches Herzzentrum Essen

    Essen

  • Asklepios Klinik St. Georg Hamburg

    Hamburg

  • Universitares Herzzentrum Hamburg GmbH

    Hamburg

  • Universitatsklinikum Jena

    Jena

  • Herzzentrum Leipzig GmbH

    Leipzig

  • Klinikum Lüdenscheid

    Lüdenscheid

  • St. Marien Hospital Lunen

    Lünen

  • University Hospital of Magdeburg

    Magdeburg

Other trials in Germany

Australia5 sites

  • Flinders Medical Center Adelaide

    Adelaide

  • Princess Alexandra Hospital

    Brisbane

  • St. Vincent's Hospital

    Melbourne

  • Sir Charles Gairdner Hospital

    Nedland

  • Royal Perth Hospital

    Perth

Other trials in Australia

Israel5 sites

  • Barzilai Medical Center

    Ashkelon

  • Soroka Medical Center

    Beersheba

  • Hadassah Medical Organization

    Jerusalem

  • Sourasky Medical Center

    Tel Aviv

  • Sheba Medical Center

    Tel HaShomer

Other trials in Israel

United Kingdom5 sites

  • University Hospitals of Coventry and Warwickshire

    Coventry

  • Glenfield Hospital

    Leicester

  • St. George's Hospital

    London

  • St. Thomas' Hospital

    London

  • Russells Hall Hospital

    West Midlands

Other trials in United Kingdom

Denmark4 sites

  • Aalborg Sygehus

    Aalborg

  • Skejby Sygehus Aarhus

    Aarhus

  • Rigshospitalet

    Copenhagen

  • Gentofte Hospital

    Hellerup

Other trials in Denmark

Italy4 sites

  • A.O.U. Consorziale Policlinico di Bari

    Bari

  • A.O. Spedali Civili di Brescia

    Brescia

  • P.O. Santa Maria di Loreto Nuovo

    Naples

  • A.O.U. Maggiore della Carita

    Novara

Other trials in Italy

Switzerland4 sites

  • Hopitaux Universitaires de Geneve

    Geneva

  • CHU Vaudois Lausanne

    Lausanne

  • Triemli Hospital (Stadtspital Triemli)

    Zurich

  • University of Zurich Hospital

    Zurich

Other trials in Switzerland

Czechia3 sites

  • Olomouc University Hospital

    Olomouc

  • IKEM - Institute for Clinical and Experimental Medicine

    Prague

  • Na Homolce Hospital

    Prague

Other trials in Czechia

France3 sites

  • Nouvelles Cliniques Nantes

    Nantes

  • CHU Pontchaillou de Rennes

    Rennes

  • CHU Charles Nicolle

    Rouen

Other trials in France

Belgium2 sites

  • OLV Hospital (OLV Ziekenhuis) Aalst

    Aalst

  • Universitair Ziekenhuis Brussel

    Brussels

Other trials in Belgium

Canada2 sites

  • Edmonton Cardiology

    Edmonton

  • UHN Toronto General Hospital

    Toronto, Ontario

Other trials in Canada

Netherlands2 sites

  • VU MC Amsterdam

    Amsterdam

  • Leiden University Medical Center

    Leiden

Other trials in Netherlands

Poland2 sites

  • Instytut Kardiologii

    Warsaw

  • 4 Wojskowy Szpital Kliniczny

    Wroclaw

Other trials in Poland

Portugal2 sites

  • Hospital Santa Maria de Lisboa

    Lisbon

  • Hospital Santa Marta

    Lisbon

Other trials in Portugal

Spain2 sites

  • University of Alicante General Hospital

    Alicante

  • Hospital Clinic of Barcelona

    Barcelona

Other trials in Spain

Austria1 site

  • LKH Universitatsklinikum Graz

    Graz

Other trials in Austria

About this study

The EchoCRT trial evaluates the effects of Cardiac Resynchronization Therapy (CRT) on mortality and morbidity of subjects with heart failure due to left ventricular systolic dysfunction, already receiving optimized HF medication, with a narrow QRS width (< 130 ms) and echocardiographic evidence of ventricular dyssynchrony.

Being tested
Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
Keywords
Cardiac Resynchronization Therapy, Heart Failure, Ventricular Dyssynchrony, Mechanical Dyssynchrony, Intraventricular Dyssynchrony, Echocardiography, Normal QRS, Heart Disease, EchoCRT
Medical subject headings
Heart Failure, Heart Diseases

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)Device

    Also called Lumax HF-T CRT-D system

    All patients will receive a commercially available BIOTRONIK Lumax HF-T CRT-D system with ICD back-up enabled. Patients will be randomized to CRT=ON or CRT=OFF.

Study groups in NCT00683696
Study groupRoleWhat they receive
CRT=ONExperimentalCardiac Resynchronization Therapy activated.
Receives: Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)
CRT=OFFActive comparatorCardiac Resynchronization Therapy deactivated.
Receives: Device: Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D)

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death

    The primary efficacy endpoint will evaluate the effect of CRT=ON versus CRT=OFF in time to event of a combined endpoint of all-cause mortality or first hospitalization for worsening heart failure.

    Measured: From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years

  2. Number of Subjects That Underwent Implant Attempt Without System- or Implant-Related Complications (Complication-Free)

    The primary safety endpoint will evaluate the complication-free rate of the Lumax HF-T CRT-D devices in the narrow QRS subject population.

    Measured: 6 months

Secondary outcomes (5)

  1. Rate of Hospitalizations for Worsening Heart Failure (Hospitalizations Per Subject-year)

    Evaluate the effects of CRT=ON compared to CRT=OFF on the rate of hospitalization for worsening heart failure (WHF).

    Measured: Study duration from randomization to study exit

  2. New York Heart Association (NYHA) Classification Change

    Evaluate the effects of CRT=ON compared to CRT=OFF in relation to the change in NYHA classification.

    NYHA classes:

    Class I - Subjects with cardiac disease, but without resulting limitation of physical activity. Ordinary physical activity does not cause undue fatigue, palpitation,dyspnea, or anginal pain.

    Class II - Subjects with cardiac disease resulting in slight limitation of physical activity. They are comfortable at rest. Ordinary physical activity results in fatigue, palpitation, dyspnea, or anginal pain.

    Class III - Subjects with cardiac disease resulting in marked limitation of physical activity. They are comfortable at rest. Less than ordinary activity causes fatigue, palpitation, dyspnea, or anginal pain.

    Class IV - Subjects with cardiac disease resulting in inability to carry on any physical activity without discomfort. Symptoms of cardiac insufficiency or of anginal syndrome may be present even at rest. If any physical activity is undertaken, discomfort is increased.

    Measured: 6 months

  3. Change in Quality of Life (QOL) Scores From Baseline to 6-Month Follow-up

    Quality of Life was evaluated using the Minnesota Living with Heart Failure (MLHF) Quality of Life (QOL) Questionnaire.The questionnaire consists of 21 questions to measure the subjects' perception of how their HF and its treatment affected their ability to live as they wanted during the last month. The questions describe different ways in which some people are affected (i.e. physical, socioeconomic, and psychological impairments). If a question does not apply to a subject or is not related to their HF, then they can answer with a 0. If it does apply to them, then they can rate (from 1 to 5) how much it has affected them. From the 21 questions, the lowest possible total score is 0, and the highest possible total score is 105. A lower score is desirable. Therefore, a negative change in QOL score from baseline to 6 months represents an improvement in quality of life, while a positive change in QOL score from baseline to 6 months represents a worsening in quality of life.

    Measured: Changes between baseline and 6 months

  4. Composite Score of Death, Hospitalization for Worsening Heart Failure and Change in Quality of Life (QOL)

    Evaluate the effects of CRT=ON compared to CRT=OFF in relation to a composite endpoint of all-cause mortality, hospitalization for worsening heart failure and change in the MLHF Quality of Life Questionnaire.

    This composite endpoint used a weighted scoring scale based on the African-American Heart Failure Trial (A-HeFT) study Endpoint Score. (Taylor, AL, Ziesche, S, Yancy, C, et al. Combination of Isosorbide Dinitrate and Hydralazine in Blacks with Heart Failure. N Engl J Med 2004; 351:2049-57.)

    Composite Endpoint Scoring:

    Vital Status:

    Death (-3),

    Survival to end of trial (0),

    Hospitalization:

    1st hospitalization for HF (-1),

    No hospitalization (0),

    QOL score:*

    Improvement by ≥ 10 units (+2),

    Improvement by 5-9 units (+1),

    Change by < 5 units (0),

    Worsening by 5-9 units (-1),

    Worsening by ≥ 10 (-2).

    Possible total score -6 to +2.

    *QOL score details are provided in Secondary Outcome Measure 5.

    Measured: Composite of death, worsening heart failure hospitalization (up to 24 months), and change in QOL (at 6 months)

  5. Number of Subjects With All-cause Mortality

    Evaluate the all-cause mortality rate between the CRT=ON compared to CRT=OFF group.

    Measured: From date of randomization up to date of study exit, with a mean treatment duration of 1.6 years

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted23 May 2008 (estimated)
  2. Study startAug 2008
  3. Primary completionMar 2013
  4. Study completionMar 2013

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase 2/3
Primary purpose
Treatment
Allocation
Randomised
Intervention model
Parallel groups
Masking
Triple blind
Who is masked
Participant, Investigator, Outcomes assessor
Enrolment
1,680 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT00683696
Sponsor's protocol ID
EchoCRT
Acronym
EchoCRT
Status last verified
Jan 2018
First submitted
30 Aug 2007
Last updated
17 Jan 2018
Data monitoring committee
Yes

Publications

  • Varma N, Sogaard P, Bax JJ, Abraham WT, Borer JS, Dickstein K, Singh JP, Gras D, Holzmeister J, Brugada J, Ruschitzka F. Interaction of Left Ventricular Size and Sex on Outcome of Cardiac Resynchronization Therapy Among Patients With a Narrow QRS Duration in the EchoCRT Trial. J Am Heart Assoc. 2018 May 27;7(11):e009592. doi: 10.1161/JAHA.118.009592.

    PubMed 29807890

  • Tayal B, Gorcsan J 3rd, Bax JJ, Risum N, Olsen NT, Singh JP, Abraham WT, Borer JS, Dickstein K, Gras D, Krum H, Brugada J, Robertson M, Ford I, Holzmeister J, Ruschitzka F, Sogaard P. Cardiac Resynchronization Therapy in Patients With Heart Failure and Narrow QRS Complexes. J Am Coll Cardiol. 2018 Mar 27;71(12):1325-1333. doi: 10.1016/j.jacc.2018.01.042.

    PubMed 29566816

  • Steffel J, Varma N, Robertson M, Singh JP, Bax JJ, Borer JS, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J, Brugada J, Abraham WT, Ruschitzka F. Effect of Gender on Outcomes After Cardiac Resynchronization Therapy in Patients With a Narrow QRS Complex: A Subgroup Analysis of the EchoCRT Trial. Circ Arrhythm Electrophysiol. 2016 Jun;9(6):e003924. doi: 10.1161/CIRCEP.115.003924.

    PubMed 27282848

  • Ruschitzka F, Abraham WT, Singh JP, Bax JJ, Borer JS, Brugada J, Dickstein K, Ford I, Gorcsan J 3rd, Gras D, Krum H, Sogaard P, Holzmeister J; EchoCRT Study Group. Cardiac-resynchronization therapy in heart failure with a narrow QRS complex. N Engl J Med. 2013 Oct 10;369(15):1395-405. doi: 10.1056/NEJMoa1306687. Epub 2013 Sep 2.

    PubMed 23998714

Questions about this trial

What is this clinical trial studying?

A Phase 2/3 study testing Implantable Cardioverter Defibrillator with Cardiac Resynchronization Therapy (BIOTRONIK Lumax HF-T CRT-D) in people with Heart Failure and Ventricular Dyssynchrony, run by Biotronik, Inc. at 122 sites in 17 countries.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 13 inclusion and 23 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: stopped early, as of the sponsor's last update on 17 Jan 2018. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 122 sites in United States, Germany, Australia, Israel, United Kingdom and 12 more countries. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

What does this combined phase mean?

Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.

Phase 3 studies compare the treatment with the current standard treatment or a placebo in a large group, to confirm how well it works and watch for side effects.

Not every study follows the same path, and some studies (observational studies, device studies) have no phase.

Are results available for this study?

Yes. Results are posted in the registry (first posted 17 Apr 2014). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Composite Primary Endpoint: Number of Subjects With First Hospitalization for Worsening Heart Failure or Death (time frame: From date of randomization until date of death from any cause or date of first hospitalization for worsening heart failure, whichever came first, assessed up to date of study exit, with a mean treatment duration of 1.6 years). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT00683696, which also lists 4 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 17 Jan 2018.

AzTrials uses cookies for analytics and advertising. You can accept or reject them; the site works either way. Privacy Policy.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in
EchoCRT Clinical Trial NCT00683696 | AzTrials